NEW AMBRX BIOPHARMA INC (AMAM)

US6418711080 - Common Stock

28  +0.02 (+0.07%)

After market: 28 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

NEW AMBRX BIOPHARMA INC

NASDAQ:AMAM (3/6/2024, 7:00:01 PM)

After market: 28 0 (0%)

28

+0.02 (+0.07%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month129.32%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap12.42B
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

AMAM Daily chart

Company Profile

Ambrx Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in La Jolla, California and currently employs 66 full-time employees. The company went IPO on 2021-06-18. Ambrx Biopharma Inc. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. The company is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its ADC targeting Human epidermal growth factor receptor 2 (HER2). The company uses genetic code technology platform to discover and develop engineered precision biologics. Its genetic code technology platform allows to incorporate, in a site-specific manner, synthetic amino acids (SAA), into proteins within living cells. Its SAA incorporation technology is designed to develop a range of product candidate modality, such as modified cytokines and bispecific antibodies, and others.

Company Info

NEW AMBRX BIOPHARMA INC

10975 North Torrey Pines Road

La Jolla CALIFORNIA

P: 18588752400

CEO: Feng Tian

Employees: 66

Website: https://ambrx.com/

AMAM News

News Image3 months ago - Ambrx Biopharma Inc.Ambrx Shareholders Approve Acquisition by Johnson & Johnson

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders...

News Image4 months ago - InvestorPlace3 Dividend Stocks That Are Too Good to Ignore: Q1 Edition

Here are the three dividend stocks that will never disappoint you. Buy them while they trade at a discount.

News Image4 months ago - InvestorPlace3 Stocks to Buy That Are Up 200% or More in 2024

Each of these stocks up 200% in 2024 offer unique upside opportunities for investors, including equity arbitrage plays.

News Image4 months ago - InvestorPlaceThe 3 Biotech Stocks That Could Make Your February Unforgettable

After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.

News Image4 months ago - Halper Sadeh LLPSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AMAM, JNPR, INBX, RYZB

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image4 months ago - Kuehn Law, PLLCKuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law Firm

/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...

AMAM Twits

Here you can normally see the latest stock twits on AMAM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example